These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 36358869)

  • 1. A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors.
    Shalata W; Weissmann S; Itzhaki Gabay S; Sheva K; Abu Saleh O; Jama AA; Yakobson A; Rouvinov K
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
    Aggarwal P
    Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
    [No Abstract]   [Full Text] [Related]  

  • 3. Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.
    Mazumder A; Darji K; Smith K; Guo M
    BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
    Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
    Front Immunol; 2022; 13():984132. PubMed ID: 36189265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab.
    Olsen E; Svoboda SA; Saikaly SK; Missall TA; Motaparthi K
    Cureus; 2023 Aug; 15(8):e43230. PubMed ID: 37692698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M; Chiu MN; Pilkhwal Sah S
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous adverse effects of the immune checkpoint inhibitors.
    Collins LK; Chapman MS; Carter JB; Samie FH
    Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
    Ellis SR; Vierra AT; Millsop JW; Lacouture ME; Kiuru M
    J Am Acad Dermatol; 2020 Oct; 83(4):1130-1143. PubMed ID: 32360716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab-induced reactivation of bullous pemphigoid.
    Kaul S; Wang A; Grushchak S; Albrecht J
    Int J Dermatol; 2021 Jun; 60(6):757-758. PubMed ID: 33615441
    [No Abstract]   [Full Text] [Related]  

  • 12. Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.
    Tsiogka A; Bauer JW; Patsatsi A
    Acta Derm Venereol; 2021 Jan; 101(1):adv00377. PubMed ID: 33426566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
    Lopez AT; Khanna T; Antonov N; Audrey-Bayan C; Geskin L
    Int J Dermatol; 2018 Jun; 57(6):664-669. PubMed ID: 29630716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Rare Case of Bullous Pemphigoid Secondary to Checkpoint Inhibitor Immunotherapy: A Tense Situation.
    Wesolow JT; Jalali S; Clark LD
    Cureus; 2021 Jul; 13(7):e16169. PubMed ID: 34367779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitor-related dermatologic adverse events.
    Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
    J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
    Cosimati A; Rossi L; Didona D; Forcella C; Didona B
    J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bullous Pemphigoid Associated With Pembrolizumab Therapy for Non-Small-Cell Lung Cancer: A Case Report.
    Chatterjee T; Rashid TF; Syed SB; Roy M
    Cureus; 2022 Jan; 14(1):e21770. PubMed ID: 35251840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
    JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.